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Summary
We show that the antiapoptotic proteins BCL-2, BCL-XL,MCL-1, BFL-1, and BCL-w each bear a unique pattern of interaction
with a panel of peptides derived fromBH3domains of BH3-only proteins. Cellular dependence on an antiapoptotic protein for
survival can be decoded based on the pattern of mitochondrial sensitivity to this peptide panel, a strategy that we call BH3
profiling. Dependence on antiapoptotic proteins correlates with sequestration of activator BH3-only proteins like BID or BIM
by antiapoptotic proteins. Sensitivity to the cell-permeable BCL-2 antagonist ABT-737 is also related to priming of BCL-2 by
activator BH3-only molecules. Our data allow us to distinguish a cellular state we call ‘‘primed for death,’’ which can be
determined by BH3 profiling and which correlates with dependence on antiapoptotic family members for survival.Introduction
The BCL-2 family of proteins contains key regulators of the mi-
tochondrial (also called ‘‘intrinsic’’) pathway of apoptosis (Danial
and Korsmeyer, 2004). The family may be subdivided into three
main groups based on regions of BCL-2 homology (BH
domains) and function: multidomain antiapoptotic (BCL-2,
BCL-XL, BCL-w, MCL-1, BFL-1/A1), multidomain proapoptotic
(BAX, BAK), and BH3-only proapoptotic (BID, BIM, BAD, BIK,
NOXA, PUMA, BMF, HRK). Proapoptotic function of BH3-only
proteins requires BAX or BAK (Cheng et al., 2001; Wei et al.,
2001; Zong et al., 2001) and an intact BH3 domain (Chittenden
et al., 1995; O’Connor et al., 1998; Wang et al., 1996; Zha
et al., 1997), the only BCL-2 homology (BH) region this class
of protein possesses. The BH3 domain is an amphipathic a helix
that interacts with multidomain family members via the hydro-
phobic cleft formed by their BH1, BH2, and BH3 domains
(Cheng et al., 1996; Kelekar et al., 1997; Kelekar and Thompson,
1998; Muchmore et al., 1996; Sattler et al., 1997). BH3-only
family members serve as sentinels for cellular derangement pri-
marily by modulating function of the multidomain proteins
(Huang and Strasser, 2000; Kelekar and Thompson, 1998; Wei
et al., 2000). In response to a wide variety of damage signals, in-
cluding DNA damage, growth factor withdrawal, or oncogeneCANCER CELL 9, 351–365, MAY 2006 ª2006 ELSEVIER INC. DOI 10.10activation, BH3-only family members are activated by transcrip-
tion or posttranslational modification (Nakano and Vousden,
2001; Oda et al., 2000; Puthalakath et al., 1999; Zha et al.,
1996). Certain of these proteins (which we named activators,
including BID and BIM [Letai et al., 2002]) induce the oligomer-
ization of BAX and/or BAK resulting in mitochondrial outer mem-
brane permeabilization (MOMP) (Cartron et al., 2004; Desagher
et al., 1999; Kuwana et al., 2005; Kuwana et al., 2002; Letai et al.,
2002; Luo et al., 1998; Marani et al., 2002; Wei et al., 2000),
allowing the release of proapoptotic factors including SMAC,
AIF, and cytochrome c into the cytoplasm (Wang, 2001). Cyto-
chrome c forms a complex with APAF-1 and caspase-9 known
as the apoptosome; this holoenzyme then cleaves and activates
caspase-3, resulting in widespread proteolysis and cell death.
Antiapoptotic family members prevent death by interrupting
signaling upstream of BAX/BAK oligomerization, largely by
binding and sequestering activator BH3 domains and prevent-
ing their interaction with BAX/BAK (Cheng et al., 1996, 2001;
Kuwana et al., 2005; Letai et al., 2002). Another class of BH3-
only proteins, which we term sensitizers (Letai et al., 2002),
induce BAX/BAK oligomerization indirectly, by binding anti-
apoptotic proteins and displacing activator BH3-only proteins.
Another perspective suggests that interactions among
BH3-only proteins and BAX/BAK, if they occur at all, are of littleS I G N I F I C A N C E
With the advent of effective antagonists of antiapoptotic protein BCL-2, it is vital to understand the mechanism underlying cellular
‘‘addiction’’ to antiapoptotic proteins in the BCL-2 family. Using a panel of peptides that selectively antagonize the individual BCL-2
family members BCL-2, BCL-XL, BCL-w, MCL-1, and BFL-1, we show that cellular ‘‘addiction’’ to individual antiapoptotic proteins may
be diagnosed based on mitochondrial response to these peptides. We show that not all cells are sensitive to antagonism of antiapop-
totic proteins. Sensitive cells are ‘‘primed for death’’ with death signals carried by a select subset of proapoptotic proteins of the BCL-2
family. Somecancer cellsmaybe tonically primed for death, and thus selectively susceptible toagents that provokeormimic sensitizer
BH3-only domains.16/j.ccr.2006.03.027 351
A R T I C L EFigure 1. Binding pattern for BH3 peptide interaction with antiapoptotic BCL-2 family proteins
A: BH3 peptides used in these studies. BIDmut differs from BID by two alanine substitutions.
B: Selective binding between antiapoptotic and BH3-only family members. Dissociation constants for interactions between antiapoptotic BCL-2 family pro-
teins (left) and BH3 domains from BH3-only proteins (top) are shown in nM. Standard deviations of at least three independent measurements are in parenthe-
ses. Yellow blocks signify high-affinity binding; blue blocks and minus sign signify no observed binding (Kd >2500 nM). Activators are in purple, and sensitizers in
green. Note that, for BCL-2 binding, Kd values are lower than those previously reported (Letai et al., 2002) due to improved purity of GST-BCL-2 protein in this
assay.significance. Rather, apoptosis is triggered by the neutralization
of antiapoptotic proteins by BH3-only proteins. In this model,
the link between neutralization of antiapoptotic proteins and
MOMP remains obscure (Chen et al., 2005; Willis et al., 2005).
It has been postulated that inhibition of apoptosis is a require-
ment of oncogenesis (Green and Evan, 2002; Hanahan and
Weinberg, 2000). In what may be an attempt to meet this re-
quirement, many types of cancer overexpress antiapoptotic
BCL-2 family members. Understanding how these proteins
function is therefore critical to understanding how cancer cells
maintain survival. Here, we systematically investigate how anti-
apoptotic BCL-2 family members interact with BH3-only family
members to control MOMP and commitment to apoptosis. We
demonstrate that antiapoptotic proteins show selective affinity
for binding BH3 peptides derived from BH3-only proteins. We
further show that antagonism of antiapoptotic family members
results in MOMP only when the antiapoptotic proteins are
‘‘primed’’ with activator BH3 proteins, validating the critical
role of activator BH3 domains in activating BAX/BAK. In cell cul-
ture models, we show that activator ‘‘priming’’ can be observed
following experimentally induced death signaling, and that such
priming confers dependence on antiapoptotic family members.
Remarkably, we show that dependence on antiapoptotic BCL-2
family members can be captured functionally by the pattern of
mitochondrial sensitivity to sensitizer BH3 domains. Finally, in
a previously credentialed model of BCL-2-dependent leukemia,
we show that these cancer cells are tonically ‘‘primed’’ with ac-
tivator BH3 molecules, conferring sensitivity to sensitizers.
Hence, we show that oncogene addiction in this model has its
correlate in sensitivity to BH3 peptides that bind BCL-2.352Heretofore, two states had been identified with respect to
programmed cell death: alive and dead. We distinguish a third
state, which we call ‘‘primed for death.’’ Cells in this state require
tonic antiapoptotic function for survival. This state can be char-
acterized based on sensitivity to sensitizer BH3 domains and
BCL-2 antagonists like ABT-737.
Results
Antiapoptotic proteins demonstrate distinct profiles
of binding sensitizer BH3 peptides
To determine selectivity in interactions among antiapoptotic
BCL-2 family members and BH3 domains of BH3-only proteins,
we used fluorescence polarization binding assays (FPA). Anti-
apoptotic proteins BCL-2, BCL-XL, MCL-1, BCL-w, and BFL-1
were purified from transfected bacteria as GST fusion proteins.
BH3 domains were synthesized as 20–25-mers as shown in
Figure 1A. Oligopeptides used for FPA were tagged with an
N-terminal FITC moiety. Figure 1B quantitates binding by disso-
ciation constants.
It is immediately notable that the antiapoptotic family mem-
bers may be distinguished from each other based on affinity
for individual BH3 domains. For instance, BCL-XL may be distin-
guished from BCL-2 and BCL-w by its much greater affinity for
HRK BH3. Otherwise, though there are quantitative distinctions
among binding patterns of BCL-2, BCL-XL and BCL-w, the qual-
ititative binding patterns are quite similar, suggesting similarity in
the hydrophobic binding pockets of these three molecules.
In contrast with this group, MCL-1 does not bind BAD BH3, in
agreement with data generated by pull-down (Opferman et al.,CANCER CELL MAY 2006
A R T I C L E2003), yeast two-hybrid (Leo et al., 1999), and surface plasmon
resonance (Chen et al., 2005) assays. Murine NOXA is unique
among the known BH3-only proteins in that it possesses two
putative BH3 domains (Oda et al., 2000). It is significant that,
while the other four proteins interact with neither of the NOXA
BH3 domains tested, MCL-1 interacts with both. This suggests
that the interaction between NOXA and MCL-1 is indeed biolog-
ically significant, congruent with prior findings (Chen et al.,
2005). The ability to bind both BH3 domains suggests the pos-
sibility of multimeric interactions between MCL-1 and murine
NOXA, or alternatively, differential control over exposure of the
two BH3 domains in NOXA.
Also distinct is BFL-1. While it binds BID and BIM, it binds only
PUMA among the sensitizers tested. It is also notable that the
activators BID and BIM BH3 are bound by all of the antiapo-
ptotics tested, distinguishing them from the sensitizers, which,
except PUMA, show a more selective pattern of binding. Of ad-
ditional note is that the BH3 domain obtained from BNIP-3a
binds to none of the proteins tested and does not activate
BAX or BAK. While we cannot exclude the possibility that
BNIP BH3 interacts with an untested multidomain pro- or anti-
apoptotic BCL-2 family member, it is also possible that BNIP-3a
does not function as a BH3 family member at all (Ray et al.,
2000).
Dependence on individual antiapoptotic proteins
may be deduced by pattern of sensitivity to sensitizer
BH3 peptides; Inhibition of antiapoptotic protein
is insufficient for MOMP unless activator tBID is present
We have previously shown that the BH3 domains of BID and BIM
possess the ability to induce BAX and BAK oligomerization and
cytochrome c release in a purified mitochondrial system (Letai
et al., 2002). We termed this class of BH3 domain ‘‘activators.’’
BH3 domains from BAD and BIK (which we termed ‘‘sensi-
tizers’’) were unable to induce cytochrome c release on their
own. However, when an activator was bound and sequestered
by BCL-2, preventing interaction of the activator with BAX or
BAK, sensitizers could provoke mitochondrial apoptosis by
competitively inhibiting BCL-2’s binding of the activator, freeing
the activator to oligomerize BAX or BAK and induce cytochrome
c release. Thus, the two sensitizer BH3 domains were shown to
be antagonists of BCL-2 antiapoptotic function. The ability to
antagonize BCL-2 function correlated with high-affinity binding
to BCL-2.
In Figure 1B, the expanded range of BH3 domains tested in
the present study demonstrate distinct patterns of binding to
antiapoptotic proteins. To test if selective binding corresponded
to ability of individual BH3 domains to selectively antagonize
antiapoptotic function, we constructed a purified mitochondrial
system in which we reconstituted the critical apoptosis deci-
sion-making molecular machinery. For the activator function,
we used caspase-8 cleaved BID protein, tBID. tBID is an arche-
typical activator protein, capable of inducing BAX/BAK oligo-
merization and cytochrome c release in purified mitochondria
(Wei et al., 2000) and synthetic liposomes (Kuwana et al.,
2002, 2005). tBID’s induction of cytochrome c release and
apoptosis requires BAX or BAK (Cheng et al., 2001; Wei et al.,
2001). The multidomain proapoptotic function was provided
by the BAK that resides in mouse liver mitochondria; mouse liver
mitochondria contain no detectable BAX protein (Letai et al.,
2002). The dominant antiapoptotic function was provided byCANCER CELL MAY 2006one of the five different recombinant antiapoptotic proteins
used in the binding assays. BH3 peptides provided the sensi-
tizer function.
As cytochrome c release is the readout for our system, it was
important to test whether our peptides by themselves release
cytochrome c in mouse liver mitochondria like activators BID
or BIM BH3 (Letai et al., 2002). In Figure 2A, we confirm that
none of the sensitizer BH3 peptides by themselves can induce
cytochrome c release significantly above background, even at
concentrations 10-fold higher than those used in Figures 2B–
2F. While we had previously shown this for BAD, BIK, NOXA
A, and NOXA B BH3s, this is to our knowledge the first time
this finding has been described for the HRK, BNIP, PUMA,
and BMF BH3 domains.
In each of the subsequent panels, cytochrome c release by
tBID is demonstrated, followed by inhibition of cytochrome c re-
lease by addition of either BCL-2 (Figure 2B), BCL-XL (Figure 2C),
BCL-w (Figure 2D), MCL-1 (Figure 2E), or BFL-1 (Figure 2F). We
then tested the ability of our panel of BH3 domains to antagonize
antiapoptotic protection as measured by cytochrome c release.
Remarkably, in each case, the ability to antagonize antiapo-
ptotic function maps to the binding specificities in Figure 1B.
This is important confirmation that the binding pattern eluci-
dated in Figure 1B corresponds to biological function.
It is important to emphasize that treatment with sensitizer
peptides alone, even those that bind and antagonize all the anti-
apoptotics tested, such as PUMA BH3, or the combination of
NOXA and BAD BH3 is insufficient to cause cytochrome c re-
lease (Figure 2A). Furthermore, when the panel of sensitizer
BH3 peptides was tested in the presence of the antiapoptotic
protein BCL-XL, there was still no cytochrome c release, for-
mally ruling out the possibility that the BH3 peptides were some-
how directly converting antiapoptotic proteins to a proapoptotic
function (Figure S1 in the Supplemental Data available with this
article online). To induce MOMP and cytochrome c release,
there appears to be an absolute requirement for an activator
function, here provided by the tBID protein.
These data critically demonstrate that our panel of peptides
can determine whether a mitochondrion depends on an anti-
apoptotic protein to maintain integrity. Furthermore, the identity
of the critical antiapoptotic protein can be deduced based on
the pattern of sensitivity to our panel of sensitizer BH3 peptides.
We call this strategy BH3 profiling.
Sensitizers displace activators
from antiapoptotic proteins
Since sensitizer BH3 peptides cannot induce cytochrome c re-
lease on their own but can induce cytochrome c release when
activator and antiapoptotic proteins are present, in a pattern
that mirrors their binding to antiapoptotic proteins, we hypothe-
sized that the sensitizers are displacing activators from the anti-
apoptotic proteins. As one test of this hypothesis, we tested the
ability of sensitizer peptides to displace tBID from antiapoptotic
protein Bcl-w. In Figure 3A, tBID is displaced from BCL-w by
sensitizer BH3 peptides in a pattern that replicates the pattern
in Figure 2D. As an additional test, we examined displacement
of the activator BIM BH3 peptide from BCL-2 and MCL-1 by
BAD and NOXA BH3 peptides. In Figure 3B, consistent with Fig-
ure 1B, BAD BH3 efficiently displaces BIM BH3 from BCL-2, but
not MCL-1, whereas NOXA A BH3 efficiently displaces BIM from
MCL-1, but not BCL-2. These experiments support the ability of353
A R T I C L EFigure 2. Pattern of antiapoptotic functional antagonism matches binding chart
Mouse liver mitochondria were treated as indicated, and cytochrome c release was measured. Peptide concentrations were 10 mM unless otherwise indi-
cated; tBID concentration was 13 nM.
A: Panel of sensitizer BH3 peptides induces no cytochrome c release, even at 100 mM.
B: tBID treatment induces cytochrome c release (first bar), which is inhibited by BCL-2 (1.2 mM, second bar). The panel of sensitizer BH3 peptides antagonize
BCL-2 protection as indicated by restoration of cytochrome c release. Note that pattern of release mirrors pattern of BCL-2 binding in Figure 1B.
C–F: Remaining panels are analogous except that the following antiapoptotic proteins are used: 0.25 mM BCL-XL (C), 6.3 mM BCL-w (note tBID 43 nM this
experiment) (D), 1.1 mM MCL-1 (E), 2.4 mM BFL-1 (F). DMSO (1%) is included as a solvent control. Note that, in each case, restoration of cytochrome c release
corresponds to a high-affinity interaction in Figure 1B. Average and standard deviation from at least three independent assays performed for each antiapo-
ptotic protein are shown.sensitizer BH3 peptides to displace activators from the anti-
apoptotic binding cleft.
A cellular requirement for BCL-2 corresponds
to a ‘‘BCL-2 pattern’’ of mitochondrial sensitivity
to the sensitizer BH3 panel
In order to test whether mitochondrial dependence on individual
antiapoptotic protein function can be correlated with cellular be-
havior, we investigated cellular models of defined antiapoptotic
dependence. We first tested whether a cellular requirement
for BCL-2 for survival correlates with the BCL-2 signature of
mitochondrial sensitivity to sensitizer BH3 domains found in
Figure 2B. The prolymphocytic murine FL5.12 cell line requires354IL-3 to maintain survival. Apoptosis induced by IL-3 withdrawal
is inhibited by overexpression of BCL-2 (Figure 4A). Therefore,
BCL-2-overexpressing FL5.12 (FL5.12-BCL-2) cells deprived
of IL-3 are a model of BCL-2-dependent survival. FL5.12-
BCL-2 cells grown in the presence of IL-3 are examples of
BCL-2-independent cells.
While the dependence on BCL-2 of IL-3-deprived FL5.12 cells
is demonstrated genetically in Figure 4A, we confirmed the de-
pendence using a cell-permeable BCL-2 antagonist. ABT-737
has been shown to antagonize BCL-2 (and BCL-XL and
BCL-w) (Oltersdorf et al., 2005). In agreement with the prior re-
port, ABT-737 induced cell death in the IL-3-starved, but not
the IL-3-replete BCL-2-protected cells (Figure 4B). Moreover,CANCER CELL MAY 2006
A R T I C L EFigure 3. Sensitizer BH3 peptides displace activator BH3 proteins from antiapoptotic proteins
A: GST pull-down assay. GST-BCL-w (or point mutant R96P) was combined with tBID protein and the indicated peptides (10 mM). The BH1 domain R96P mutant
of BCL-w lacks the ability to bind BH3 domains. Proteins bound to glutathione-agarose beads were eluted with glutathione and analyzed by Western blot. For
convenience, BCL-w binding pattern from Figure 1B is excerpted below.
B: Displacement of a fluorescein-tagged BIM BH3 peptide from BCL-2 and MCL-1 proteins by BAD and NOXA BH3 peptides by fluorescence depolarization.
Shown are representative plots from three independent experiments for each combination.ABT-737 was nontoxic to the unstressed IL-3-replete wild-type
(wt) FL5.12 cells. This cell death was caspase dependent, dem-
onstrating that death occurred using the apoptotic pathway
(Figure 4C).
Having credentialed a BCL-2-dependent cellular system, we
wanted to test whether this BCL-2 dependence could be iso-
lated at the level of mitochondria. We hypothesized that removal
of IL-3 would ‘‘load’’ the BCL-2 on the mitochondria with activa-
tor BH3 proteins. We further hypothesized that mitochondria
bearing ‘‘loaded’’ BCL-2 would release cytochrome c when
treated with sensitizer BH3 peptides that compete for the
BCL-2 binding cleft. The interpretation that the IL-3-starved
FL5.12-BCL-2 cells were ‘‘primed’’ for death is supported by
the rapidity of their death following ABT-737 treatment (Fig-
ure S2).
We isolated mitochondria from wt FL5.12 cells and FL5.12-
BCL-2 cells in the presence of IL-3, and from FL5.12-BCL-2
cells following 24 hr of IL-3 deprivation. Due to advanced apo-
ptosis, mitochondria could not be isolated in sufficient quantities
from wt FL5.12 cells after IL-3 deprivation. In Figure 5A, we show
that, while activators BID and BIM potently induce cytochrome c
release from mitochondria isolated from wt FL5.12 cells, the re-
maining sensitizer peptides do not (blue bars). Thus, inhibition of
antiapoptotic family members is by itself not sufficient to induce
MOMP. Next, BCL-2 overexpression inhibits release induced by
10 mM BID BH3, but not 10 mM BIM BH3, in accordance with
dose-response curves previously demonstrated (red bars) (Letai
et al., 2002). When mitochondria from FL5.12-BCL-2 cells de-
prived of IL-3 are tested, however, certain sensitizer peptides
now demonstrate the ability to induce cytochrome c release
(tan bars), and sensitivity to 10 mM BID BH3 is restored. It is
most notable that only those sensitizer peptides with high affin-
ity for BCL-2 cause MOMP. BIK BH3 induces cytochrome c re-
lease only at 30 mM in this setting, consistent with its approxi-
mately 10-fold lower affinity than BAD, PUMA, or BMF BH3 for
BCL-2. It can be seen, therefore, that cellular BCL-2 depen-
dence can be ‘‘diagnosed’’ from the pattern of mitochondrial
sensitivity to our panel of sensitizer BH3 peptides. This depen-
dence can be ‘‘diagnosed’’ whether the activator involved isCANCER CELL MAY 2006recombinant protein, as in Figure 2, or a more complex mix in-
volving more than one molecule, as is likely the case following
IL-3 withdrawal. Note that inhibition of BCL-2 alone is not suffi-
cient to induce cytochrome c release, as seen by the failure of all
of the sensitizer peptides to induce release in the IL-3-replete
FL5.12-BCL-2 mitochondria (Figure 5A). In fact, even the combi-
nation of the peptides BAD and NOXA BH3, which provide
a broad spectrum of antiapoptotic protein binding, cannot
induce cytochrome c release in the absence of an activator mol-
ecule (Figure 5B). To induce MOMP, the BCL-2 must first be
‘‘primed’’ by molecules communicating a death signal, gener-
ated by IL-3 withdrawal. We found that BCL-2 blocks apoptosis
upstream of BAX oligomerization and that BAD BH3 and ABT-
737 inhibition of BCL-2 on IL-3-starved mitochondria results in
BAX oligomerization (Figure 5C). Therefore, we hypothesized
that this death signal might be an activator BH3 protein.
BIM has previously been shown to play a role in death follow-
ing IL-3 withdrawal in FL5.12 cells (Harada et al., 2004). In
Figure 5D, we show that total cellular BIM levels, as well as levels
of BIM complexed to BCL-2, dramatically increase following
IL-3 withdrawal. It is notable that levels of BCL-2, BAX, and
BAK stay roughly constant during the same time period. These
results suggest that the activator BIM (and perhaps PUMA) is
a dynamic mediator of the death response following IL-3 with-
drawal in FL5.12 cells and that it is sequestered to prevent apo-
ptosis. Cells and mitochondria bearing ‘‘loaded’’ BCL-2 are then
‘‘addicted’’ to BCL-2 and die when BCL-2 function is antago-
nized. Furthermore, cellular BCL-2 addiction can be diagnosed
by the pattern of mitochondrial sensitivity to sensitizer BH3
domains.
Our model predicts that BCL-2 acts upstream of BAX activa-
tion by intercepting activator BH3 molecules. To test this predic-
tion, in Figure 5E, we performed immunoprecipitation with an
antibody that recognizes only the activated form of BAX, which
exposes an N terminus epitope (Desagher et al., 1999; Hsu and
Youle, 1997). We found that IL-3 withdrawal induced BAX
activation in wt FL5.12 cells, while total BAX levels remained
constant. However, when BCL-2 protected against death from
IL-3 withdrawal, it also prevented BAX conformational change,355
A R T I C L EFigure 4. IL-3 withdrawal in BCL-2-protected FL5.12 cells provides a model of
BCL-2 dependence
A: Time course of survival following IL-3 withdrawal for wtFL5.12 and
FL5.12-BCL-2 cells. Survival was imputed for cells not staining with Annexin
V by FACS analysis. Shown are average and standard deviation of three in-
dependent experiments.
B: Sensitivity to ABT-737, a BCL-2 antagonist. IL-3– cells were grown in the ab-
sence of IL-3 for 24 hr prior to initiation of treatment with compound. All cells
were treated with compounds for 24 hr prior to harvest. Viability assayed by
absence of Annexin V staining. Shown are average and standard deviation
of three independent experiments.
C: Death caused by ABT-737 is caspase dependent. (Top) Death of FL5.12
cells treated as indicated. Shown are average and standard deviation of
three independent experiments. (Bottom) PARP cleavage correlates with
cell death.356consistent with BCL-2’s sequestering activators like BIM prior to
their interaction with BAX (compare fourth and eight lanes). Fur-
thermore, treatment with ABT-737 restored cytochrome c re-
lease and BAX activation, consistent with ABT-737 functioning
by displacing activators from BCL-2.
BH3 profiling can discriminate MCL-1 cellular
dependence from BCL-2 cellular dependence
To test if our model of antiapoptotic ‘‘priming’’ could be ex-
tended beyond BCL-2 to other antiapoptotic proteins, we com-
pared the behavior of cells protected by BCL-2 with those
protected by MCL-1. The murine hybridoma 2B4 cell line is
sensitive to dexamethasone treatment.Overexpression of FLAG-
tagged MCL-1 or BCL-2 confers resistance to dexamethasone-
induced apoptosis (Figure 6A). Therefore, dexamethasone-
treated, FLAG-MCL-1-expressing cells are a model of cellular
MCL-1 dependence, while dexamethasone-treated, BCL-2-
expressing cells are a model of cellular BCL-2 dependence.
Treatment of the MCL-1-protected dexamethasone-treated
cells with ABT-737 has no effect, showing that the cells are not
dependent on BCL-2 for survival. In stark contrast, 2B4 cells pro-
tected from dexamethasone-induced apoptosis by BCL-2 are
very sensitive to ABT-737 (Figure 6B).
The cellular data provoke the prediction that mitochondria
isolated from 2B4-MCL-1 cells treated with dexamethasone
would be sensitive to NOXA and insensitive to BAD BH3, the op-
posite of the pattern observed with IL-3-starved FL5.12-BCL-2
cells. We isolated mitochondria from dexamethasone-treated
and untreated vector-transfected and FLAG-MCL-1-trans-
fected 2B4 cells. Apoptosis was too advanced to permit isola-
tion of mitochondria from dexamethasone-treated vector-trans-
fected 2B4 cells. As can be seen in Figure 6C, only mitochondria
isolated from the MCL-1-dependent cells recapitulate an ‘‘MCL-
1 pattern’’ of sensitivity to sensitizer BH3 peptides. As with the
FL5.12 cells, since sensitizer BH3 peptides cause little cyto-
chrome c release in untreated cells, it is clear that sensitizer
BH3 peptide inhibition of MCL-1 (and other antiapoptotic pro-
teins that might be present) is not by itself sufficient to induce
apoptosis. An additional death signal (initiated by dexametha-
sone treatment in this case) is needed to ‘‘prime’’ MCL-1 so
that MCL-1 antagonism by sensitizers results in mitochondrial
permeabilization. To demonstrate the robustness of this strat-
egy, we also performed BH3 profiling on 2B4 cells treated with
dexamethasone, but this time protected with BCL-2. Consistent
with our priming model, a BCL-2 pattern is revealed (Figure 6D).
Thus, MCL-1 dependence, like BCL-2 dependence, also can be
‘‘diagnosed’’ by mitochondrial sensitivity to the sensitizer BH3
panel.
As with the FL5.12 cells, we investigated whether dexameth-
asone treatment resulted in increased sequestration of an acti-
vator BH3 protein by MCL-1 and BCL-2. In Figure 6E, we show
that FLAG-MCL-1 sequesters increased amounts of BIM follow-
ing the death signaling induced by dexamethasone treatment,
as does BCL-2 (Figure 6F). Note that levels of BAX and BAK
stay constant during the treatment. Also note that it appears
that the small amount of BAX bound to cells before treatment
with dexamethasone decreases after treatment. One interpreta-
tion is that the BAX is displaced by increased levels of BIM bind-
ing to BCL-2. This is significant because it suggests that dis-
placement of BAX from MCL-1 is insufficient to induce MOMP
and death.CANCER CELL MAY 2006
A R T I C L ETo further demonstrate that the mitochondrial assays reflect
true cellular dependence, we transfected peptides via electro-
poration into FLAG-MCL-1-transfected 2B4 cells that had
been treated with dexamethasone, putatively priming MCL-1
with death signals, carried at least in part by BIM. Supporting
the cellular relevance of our mitochondrial BH3 profiling assays,
an MCL-1 pattern of response to sensitizer peptides was ob-
served (Figure 6G; compare with Figures 1B, 2E, and 6C).
Dependence on BCL-2 in a leukemia corresponds
to mitochondrial sensitivity to sensitizers
in a ‘‘BCL-2 pattern’’ and sequestration of BIM
Dependence on antiapoptotic proteins is perhaps of greatest
importance in the context of cancer, in which antiapoptotic
BCL-2 family proteins are subjects of intense investigation as
therapeutic targets. While the concept of oncogene addiction
has received attention recently (Jonkers and Berns, 2004; Wein-
stein, 2002), the molecular details of the addiction to spe-
cific oncogenes is poorly understood. We therefore turned to
a validated model of oncogene addiction, a BCL-2-dependent
murine leukemia, to examine the molecular basis for BCL-2
‘‘addiction.’’
We have previously described a mouse acute lymphocytic
leukemia model in which c-myc is constitutively expressed
and human BCL-2 is repressibly expressed. In this model,
when BCL-2 transgene expression is eliminated by administra-
tion of doxycycline, the leukemic cells undergo apoptosis, re-
sulting in rapid resolution of the leukemia (Letai et al., 2004).
This provides us with an ideal in vivo model of a BCL-2-depen-
dent cancer. We wondered if the dependence on BCL-2 was
due to a similar mechanism to that of the IL-3-deprived
FL5.12-BCL-2 cells—that is, a death signal was being initiated
and carried by an activator BH3 molecule, but BCL-2 was bind-
ing it and preventing its interaction with multidomain proapop-
totic proteins.
We isolated mitochondria from leukemia cells and exposed
them to sensitizer BH3 peptides and measured release of cyto-
chrome c. As an internal control, mitochondria were isolated
from liver from the leukemic mice in parallel (Figure 7A). The sen-
sitizer BH3 peptides were unable to induce cytochrome c re-
lease from nonmalignant hepatocyte mitochondria from the leu-
kemic mice, just as they were unable to induce cytochrome c
release from nonmalignant liver mitochondria from normal
mice (Figure 2A) or from nonmalignant FL5.12 (Figure 5A) or
2B4 mitochondria (Figure 6C). Intriguingly, certain sensitizer
BH3 peptides were capable of inducing near total cytochrome
c release from the leukemic mitochondria (Figure 7B). Signifi-
cantly, the pattern of peptides that induced release corre-
sponded exactly to those peptides that bind with high affinity
to BCL-2 (Figure 1B), namely BAD, BIK, PUMA, and BMF.
Note that, consistent with its approximately 10-fold lower affinity
than BAD BH3 for BCL-2, BIK BH3 requires a 10-fold higher
concentration to demonstrate cytochrome c release. A 10-fold
increase in NOXA A peptide concentration has no effect, consis-
tent with the extremely low affinity NOXA A has for BCL-2.
These results suggest that, in this leukemia model, death
signals are being continually initiated, and BCL-2 is required to
sequester the activator BH3 molecule to prevent apoptosis. In
contrast to the nonmalignant systems tested above, leukemic
cell BCL-2 behaves as if already ‘‘primed’’ with activator pro-
tein(s) without any further intervention, such as growth factorCANCER CELL MAY 2006withdrawal or dexamethasone treatment. In Figure 7C, we
show that BIM is expressed in the leukemia cells, and it is bound
by BCL-2. Supporting the signal importance of BIM in transmit-
ting death signals in this model, BID is also present in the lysate
but is not bound by BCL-2. Note that PUMA is also found to be
bound by BCL-2, consistent with a report showing that PUMA
deficiency could accelerate myc-induced lymphomagenesis
(Hemann et al., 2004). Since in our hands the PUMA BH3 lacks
the ability to directly activate BAX or BAK, we hypothesize that
PUMA is acting as a sensitizer in this context, in effect decreas-
ing the amount of BCL-2 available to bind BIM and possibly BAX
or BAK.
If BCL-2 maintains survival of this leukemia cell primarily by
sequestering BIM, then one would predict that BIM loss of func-
tion could substitute for BCL-2 overexpression to cooperate
with c-myc in leukemogenesis. In fact, this experiment has al-
ready been performed. It was found that BIM deficiency can
indeed cooperate with c-myc to produce a pre-B lymphocytic
leukemia like the one produced here by the cooperation of
BCL-2 overexpression with c-myc (Egle et al., 2004). These re-
sults support a model in which BCL-2 is necessary for survival
of our leukemia largely because it is required to sequester
BIM, preventing activation of BAX/BAK and subsequent
MOMP. The leukemia cells are therefore neither normal and
healthy, nor dead, but rather primed for death.
BH3 profiling predicts sensitivity to ABT-737
As another test of the ability of BH3 profiling to detect in vivo
BCL-2 dependence, we turned to two small cell lung cancer
(SCLC) cell lines that were sensitive to treatment with ABT-737
in vitro and in an in vivo murine xenograft model (Oltersdorf
et al., 2005). Both H146 and H1963 demonstrate a pattern of
sensitivity diagnostic of BCL-2 sensitivity (Figure 7D). This pro-
vides further support, in addition to the results of Figures 4, 5,
and 6, that mitochondrial BH3 profiling is a powerful predictor
of what cells are sensitive to BH3 mimetic drugs in vitro and
in vivo.
Discussion
Life on the edge: ‘‘Primed for death’’
Conventionally, study of the apoptotic machinery has been able
to discriminate cells into two states: alive or dead. Here, we
show that certain cells live in a state that can be distinguished
by dependence on antiapoptotic proteins for survival. We de-
scribe these cells as being ‘‘primed for death,’’ as death signal-
ing has caused their antiapoptotic family members to sequester
significant quantities of proapoptotic BH3 proteins. Inhibition of
the antiapoptotic proteins in these cells, but not unprimed cells,
results in BAX/BAK oligomerization and MOMP. We suggest,
therefore, that there are three functionally distinguishable states
with respect to programmed cell death: unprimed, primed for
death, and dead. We suggest that the state of being primed
for death is a continuum, as the magnitude of BH3 proteins prim-
ing the mitochondrion can, of course, vary continuously until the
antiapoptotic reserve is overwhelmed and the cell commits to
programmed cell death. A summary of this model with reference
to the data in this paper can be found in Figure 8.
We probed mitochondria to determine a cell’s state using our
panel of sensitizer BH3 peptides, selective antagonists of anti-
apoptotic BCL-2 family members. Mitochondria that are primed357
A R T I C L EFigure 5. BCL-2 dependence is revealed by mitochondrial sensitivity to BCL-2 binding BH3 peptides
A:Cytochrome c release induced by BH3 peptides (10 mM) from mitochondria isolated from wtFL5.12 cells grown in the presence of IL-3 (blue bars); FL5.12-BCL-
2 cells grown in the presence (red bars) or absence (tan bars) of IL-3 for 24 hr. Note that BH3 sensitizer peptides, which tightly bind BCL-2 in Figure 1, are effective
antagonists of BCL-2 protection. Shown are average and standard deviation of three independent experiments. For convenience, BCL-2 binding pattern
from Figure 1 is excerpted below.
B: Combination of NOXA and BAD BH3 induces no cytochrome c release from mitochondria isolated from wt and BCL-2 FL5.12 cells grown in the presence of
IL-3. Shown are average and standard deviation of three independent experiments.358 CANCER CELL MAY 2006
A R T I C L Efor death are dependent on antiapoptotic protein function to
prevent MOMP, so that they release cytochrome c when ex-
posed to sensitizer BH3 peptides (Figures 2B–2F, 5A, 6C, 6D,
7B, and 7D). In contrast, unprimed cells do not release cyto-
chrome c when exposed to sensitizer BH3 peptides. In theory,
any cell from which mitochondria can be isolated can therefore
be so tested and categorized as being primed or unprimed.
Testing of mitochondria directly has the advantage of eliminat-
ing any contribution of transcription, translation, or posttransla-
tional modification events that might be triggered by transfec-
tion of peptide, protein, or expression vector into a living cell.
A ‘‘snapshot’’ of the apoptotic state at a given time may be taken
with minimal perturbation of the extant apoptotic machinery. In
summary, we were able to capture information about a funda-
mental aspect of cellular physiology in an assay that can be per-
formed using primary or cultured cells in a single day.
Importantly, we link mitochondrial behavior to whole-cell
behavior in several models. Mitochondria were primed when
cells were enduring a physiologic challenge, and BH3 profiling
revealed a dependence on antiapoptotic proteins only when
a cellular dependence was also demonstrated. In the case of
FL5.12 cells, cells and mitochondria became primed for death
only after IL-3 withdrawal. For 2B4 cells, cells and mitochondria
were primed for death only after dexamethasone treatment. For
the primary BCL-2-dependent leukemia cells, the genomic
instability, myc oncogene activation, and checkpoint violation
inherent to the cancer phenotype were sufficient to induce mito-
chondrial priming without further external intervention. The
SCLC cell lines H164 and H1963 that revealed a BCL-2 pattern
of sensitivity to BH3 profiling likewise are sensitive to the BCL-2
antagonist ABT-737. In each case, mitochondrial studies cor-
rectly diagnosed the cellular dependence on an antiapoptotic
BCL-2 family member. Furthermore, the identity of the individual
family member could be decoded based on the pattern of mito-
chondrial sensitivity to our peptide panel.
An implication of our results is that in some cells, like IL-3-
replete FL5.12-BCL-2 cells, BCL-2 overexpression provides
extra antiapoptotic reserve. In others, like the murine leukemias,
high levels of BCL-2 are present, but the BCL-2 is so highly
occupied by activator BH3 proteins that the cell has very poor
antiapoptotic reserve and is actually primed for death.
The binding code
An important property of our panel of sensitizer BH3 peptides is
its ability to distinguish among the antiapoptotic proteins based
on binding specificity. Others have recently demonstrated sim-
ilar selectivity in interaction among BH3 peptides and antiapo-
ptotic proteins using a different technique, surface plasmon res-
onance (SPR) (Chen et al., 2005). While dissociation constants
were not explicitly determined, the overall pattern of binding
was similar, with some notable differences. The binding of
HRK BH3 peptide, restricted to BCL-XL in our work, wasCANCER CELL MAY 2006promiscuous throughout the antiapoptotic proteins tested by
SPR. BFL1/A1, which bound only PUMA among the sensitizer
BH3 peptides in our work, bound BIK, HRK, and NOXA as well
in the work by Chen et al. There are several possible explana-
tions for these differences. First, the peptides are not identical.
Their peptides were 26 amino acids in length, while those we
use are shorter (Figure 1A). In addition, they do not test direct
binding of the peptides to the antiapoptotic proteins, as we
did by fluorescence polarization, but rather test the ability of
each of the peptides to displace a BIM BH3 peptide from the
antiapoptotic protein by SPR. We find our peptide panel partic-
ularly useful, as it allows us to distinguish BCL-XL protection
from the rest due to its selective binding of HRK BH3. Further-
more, our demonstration that MCL-1 selectively binds both
murine NOXA BH3 peptides suggests biological relevance to
the binding pattern observed.
Do these interactions between BH3 peptides and antiapo-
ptotic proteins mirror protein-protein interactions in actual cellu-
lar systems? Consistent with our binding chart, we have shown
that MCL-1 preferentially binds BIM but not BAD, governing mu-
rine lymphocyte dependence on MCL-1 for survival (Opferman
et al., 2003). A yeast two-hybrid interaction study supports the
specificity we found for BAD’s binding of antiapoptotic family
members in Figure 1B (Bae et al., 2001). Others (Chen et al.,
2005) showed that interactions of proteins overexpressed in
cells showed fidelity with the patterns found in both our systems.
Since BH3 domains are the critical ligands for the binding
pockets of antiapoptotic proteins, we expect our BH3 peptide
binding patterns to be consistent with in vivo protein-protein
interaction specificity. Since length of peptide might affect func-
tion, a longer, 26 amino acid HRK peptide was tested. While
lengthening the peptide increased slightly its ability to antago-
nize BCL-2 and MCL-1 in cytochrome c release assays, it still
did not demonstrate activator function (data not shown). It is
nonetheless possible that different conformations or posttrans-
lational modifications play a role in vivo that was not evaluated in
our binding assays. Regardless, our peptide panel captures
binding differences that allow it to function as a diagnostic of
antiapoptotic protein dependence. BCL-2 and BCL-w are
most similar, with BCL-XL distinguished by its binding to HRK
BH3. MCL-1 is quite different, binding both NOXA peptides
but not BAD, and BFL-1 binds none of the sensitizers except
PUMA. These binding specificities suggest, moreover, that it
is possible for cells to adjust sensitivity to distinct apoptotic
insults by adjusting levels of individual BCL-2 family member
expression.
The basic apoptotic paradigm
Our results shed light on a controversial issue—how interactions
among BCL-2 family members control MOMP. Our results con-
sistently show that ligation of antiapoptotic family members
alone is insufficient to induce MOMP. Rather, antiapoptoticC: Mitochondria isolated from FL5.12-BCL-2 cells grown in the absence of IL-3 for 24 hr were treated with NOXA A or BAD peptides (30 mM) or ABT-737 or control
enantiomer at 10 mM for 35 min. Mitochondrial pellets were subjected to chemical crosslinking as previously described (Letai et al., 2002).
D: Immunoblots of FL5.12-BCL-2 whole-cell lysates (left) and samples immunoprecipitated by an antibody directed against the human BCL-2 transgene prod-
uct (right). Numbers at top refer to hours after IL-3 withdrawal. Control lane performed without anti-human BCL-2 antibody in pull-down at right. Negative
control immunoprecipitation using anti-human BCL-2 antibody on lysates from IL-3-starved FL5.12-BCL-XL cells yielded no bands (data not shown).
E: BCL-2 blocks apoptosis upstream of BAX activation. wt or BCL-2-expressing FL5.12 cells were exposed to IL-3 withdrawal as indicated. BAX was immunopre-
cipitated using an antibody recognizing all BAX conformations (D21) or only the activated conformation with N-terminal exposure (NT). Death induced in the
cells is indicated below. At right, mitochondria isolated from IL-3-starved cells were treated with ABT-737 or control enantiomer, and immunoprecipitation with
NT performed as indicated. CD56 indicates control immunoprecipitation by an irrelevant antibody recognizing CD56.359
A R T I C L EFigure 6. BH3 profiling discriminates BCL-2 and MCL-1 dependence
A: MCL-1 and BCL-2 inhibit cell death induced by dexamethasone in 2B4 cells. 2B4 cells transfected with Flag-MCL-1, BCL-2, or empty vector constructs were
cultured for 24 hr in the presence of the indicated concentration of dexamethasone. Viability determined by absence of Annexin V staining by FACS. Shown
are average and standard deviation of three independent experiments.
B: BCL-2 antagonist ABT-737 has no effect on wt or MCL-1-dependent 2B4 cells but kills BCL-2-dependent cells. 2B4 cells were incubated for 24 hr with dexa-
methasone and either ABT-737 or enantiomer for 24 hr. Shown are average and standard deviation of three independent experiments.
C:Mitochondria isolated from 2B4 cells treated as indicated were exposed to BH3 peptides at the concentrations indicated. Cytochrome c release is induced
by MCL-1 binding sensitizer BH3 peptides only when mitochondria are derived from MCL-1-dependent cells. Shown are average and standard deviation of
three independent experiments. For convenience, MCL-1 binding pattern from Figure 1 is excerpted below.360 CANCER CELL MAY 2006
A R T I C L EFigure 7. Leukemia mitochondria are uniquely sensitive to BCL-2 antagonism by sensitizer BH3 peptides
Aand B:Cytochrome c release by BH3 peptides (10 mM, unless otherwise noted) using mitochondria isolated from liver (A) and BCL-2-dependent leukemia (B)
from the same animal as A. For convenience, BCL-2 binding pattern from Figure 1 is excerpted below. Shown are average and standard deviation of three
independent experiments, except 30 and 100 mM treatments, which were performed once.
C: Immunoblot of samples from a BCL-2-dependent leukemia. First lane shows a whole-cell lysate, 25 mg loaded; second lane shows products of an immu-
noprecipitation using an antibody against the human BCL-2 transgene product; third lane shows a control with Protein A beads alone; fourth lane shows con-
trol immunoprecipitation using an irrelevant hamster monoclonal antibody recognizing murine CD-40.
D: BH3 profiling predicts ABT-737 sensitivity of SCLC cell lines. Mitochondria were isolated from two SCLC cell lines, H146 and H1963, and exposed to panel of
BH3 peptides. Cytochrome c release quantitated by ELISA. n = 3 for each and the error bars represent the standard deviation.inhibition causes MOMP only when an activator is present that
can be freed from the antiapoptotic protein to activate BAX or
BAK. Based on these results, we propose a model of BCL-2
member interaction summarized in Figure S3. Our studies pro-
vide strong evidence that our earlier model (Letai et al., 2002)
of a sensitizer/activator dichotomy governing interactions of
BH3-only family members with BCL-2 and BAX/BAK can be ap-
plied across a wide range of antiapoptotic and BH3-only family
members.CANCER CELL MAY 2006Strong support for this interpretation can be found in another
recent report (Kuwana et al., 2005). In a biochemically com-
pletely defined system using BAX and liposomes, it was shown
that only those BH3 domains that we have designated activators
(BID or BIM) are capable of directly activating BAX to oligomer-
ize and permeabilize liposomes. Those BH3 domains, which we
here categorize as sensitizers, were found to induce permeabi-
lization only when an activator like cleaved BID protein was
available to be displaced from an antiapoptotic protein.D: As in C, but using BCL-2-expressing 2B4 cells and 1000 nM dexamethasone.
E: Vector- or FLAG-MCL-1-transfected 2B4 cells were treated with 0 or 100 nM dexamethasone and lysed. FLAG antibody linked to agarose beads immuno-
precipitated proteins complexing with FLAG-MCL-1. Increased BIM sequestration by MCL-1 correlates with MCL-1 dependence.
F: As in E, but using BCL-2-expressing 2B4 cells and 1000 nM dexamethasone.
G: Primed FLAG-MCL-1 2B4 cells transfected with BH3 peptides illustrate an MCL-1 pattern. Dexamethasone-treated FLAG-MCL-1 2B4 cells were electropo-
rated with 100 mM of the indicated peptides and percent killing ascertained by Annexin-V staining. Note that killing by transfection with NOXA A is significantly
greater than that with BAD, recapitulating the same MCL-1 pattern observed in isolated mitochondria from this same cell line (as in C). n = 3 and the error bars
represent the standard deviation.361
A R T I C L EFigure 8. Model of selective cancer sensitivity to
sensitizer BH3 mimetic treatment
Living unprimed cells (A) are primed for death
following death stimuli (B) (IL-3 withdrawal for
FL5.12-BCL-2 cells, dexamethasone for 2B4-
MCL-1 cells). The leukemia cell is tonically primed
for death due to cancer phenotype, without
external intervention (B). Cells in the primed state
undergo apoptosis in response to antiapoptotic
antagonists (C)—those in the unprimed state
do not.Furthermore, this displacement from either BCL-XL or MCL-1
took place in accordance to a binding code consistent with
Figure 1B.
It is worth noting how our model contrasts with other models
recently proposed. Chen et al. present a model for control of ap-
optosis in which BH3-only family members provoke apoptosis
exclusively by inhibition of antiapoptotic BCL-2 family members,
without interacting with multidomain proapoptotic BAX or BAK
(Chen et al., 2005). In contrast, our results clearly demonstrate
that mere inhibition of antiapoptotic proteins is insufficient for
apoptosis. Instead, activation of BAX and/or BAK by activator
BH3-only proteins like BIM or BID is required. The same authors
also suggested, based on transfection and overexpression in
cellular systems, that the combination of NOXA and BAD is suf-
ficient to trigger apoptosis, as together they bind to a broad
range of antiapoptotic proteins. We tested this directly in both
MLM and FL5.12 mitochondria, systems in which translation
and transcription were unavailable to alter levels of activator362proteins. The combination of NOXA BH3 and BAD BH3 peptides
by themselves could not induce MOMP (Figures 2A and 5B).
However, if an activator protein (BID or BIM) was present and
sequestered by an antiapoptotic protein to which NOXA or
BAD BH3 could bind, either NOXA BH3 or BAD BH3 by itself
was effective (Figures 2B, 2E, 5A, 6C, and 6D).
It has recently been suggested that, on mitochondria contain-
ing BAK, survival is maintained when BAK is sequestered by se-
lect antiapoptotic proteins. BAK can be sequestered by MCL-1
and BCL-XL, but not BCL-2. In this model, apoptosis is initiated
when BAK is displaced from MCL-1 or BCL-XL by competition
of BH3-only proteins (Willis et al., 2005). A prediction of this
model, therefore, is that BCL-2 should be unable to prevent ap-
optosis on mitochondria bearing only BAK, but no BAX. This
model is inconsistent with the data we present here. The murine
liver mitochondria in Figure 2 contain BAK, but no BAX (Letai
et al., 2002). Figure 2B, however, demonstrates that BCL-2
can prevent tBID-induced apoptosis in this system. In addition,CANCER CELL MAY 2006
A R T I C L Ein Figure S1, inhibition of antiapoptotic function of BCL-XL by
sensitizer BH3 domains is unable to induce apoptosis; activator
tBID is required. Our data are more consistent with a model in
which BCL-2 and other antiapoptotic BCL-2 family members
inhibit BAK-dependent apoptosis by sequestering activators
like tBID and preventing their activation of BAK. Our data do
not exclude, however, the possibility that in some systems tonic
sequestration of BAK by MCL-1 or BCL-XL might play a role in
preventing apoptosis. Further studies will be necessary to deter-
mine the relative relevance of each of these models across
a range of biological systems.
We have here classified PUMA BH3 as a sensitizer. While
PUMA BH3 sometimes induced low levels of cytochrome c re-
lease in the absence of exogenous death stimuli, the levels
were always significantly lower than those found for BID and
BIM BH3. Additionally, in these cases it is possible that the
low levels of BIM already present in these cells provided the
key activator function, as can be seen in Figure 6. Some studies
have provided evidence that PUMA can indeed interact directly
with BAX (Cartron et al., 2004; Liu et al., 2003), while others sug-
gest that PUMA lacks this property (Kuwana et al., 2005). Left
untested by these prior studies is the ability of PUMA to interact
with BAK. It is notable that PUMA shares with activators BID and
BIM the ability to interact with all five antiapoptotics tested.
However, we showed that, under conditions where PUMA
BH3 could not induce cytochrome c release by itself, it could
nonetheless indirectly provoke cytochrome c release by antag-
onism of antiapoptotic proteins occupied by an activator. While
we cannot rule out that PUMA may have significant activator
function in other conditions, under the conditions tested here
its BH3 domain did not, and we were able to evaluate the spec-
trum of its sensitizer function in isolation.
An important consequence of our results is that interpretation
of experiments in apoptosis in vivo, on cells, and mitochondria
must consider whether the extent of priming of the system is
affecting results. This consideration may clarify some discrep-
ancies present in the field of apoptosis research.
Antiapoptotic oncogene addiction in cancer
It is noteworthy that, while our nonmalignant models like mouse
liver (Figure 2) and FL5.12 (Figures 4 and 5) require exogenous
death signaling to acquire a requirement for antiapoptotic pro-
teins, the cancer cells tested in these studies (like the murine
leukemia and SCLC cell lines in Figure 7) are apparently already
enduring death signaling that renders them dependent on
BCL-2.
In our murine leukemia model, BCL-2 sequesters BIM (Fig-
ure 7C), the likely explanation for BCL-2’s requirement for leuke-
mia maintenance in vivo (Letai et al., 2004). When these mito-
chondria were treated with sensitizer antagonists of BCL-2,
therefore, they required no additional activator function, as
one was already present and bound to BCL-2. Cancer cells vio-
late many normal rules, including oncogene activation (c-myc in
this case), cell cycle checkpoint violation, genomic instability,
etc. These and other abnormal properties of cancer cells pro-
voke death signals, likely producing a requirement for apoptotic
deficiency in cancer cells (Fanidi et al., 1992; Green and Evan,
2002; Hanahan and Weinberg, 2000; Schmitt, 2003). Relevant
to this model, c-myc has been shown to induce BIM expression
(Egle et al., 2004; Hemann et al., 2005). Our experiments lay
a biochemical framework for studying the widely discussedCANCER CELL MAY 2006notion that cancer cells may teeter on the brink between survival
and death.
These experiments suggest an intriguing dichotomy with po-
tentially profound therapeutic significance in cancer. It will be in-
teresting to explore the extent to which tonic activator BH3
priming of antiapoptotic proteins contributes to the preferential
sensitivity of many cancer cells to standard cytotoxic chemo-
therapy. This model suggests that there may be a natural thera-
peutic window provided between unprimed normal cells and
BH3-only protein-primed cancer cells. This is of therapeutic
significance, since our data suggest that primed cells would
likely be selectively sensitive both to sensitizer BH3 mimetics
like ABT-737 as well as to agents that provoke sensitizer BH3-
only protein expression. Since conventional chemotherapeutic
agents do activate or induce sensitizer BH3-only proteins, it
may be that the priming by death signals we identify may under-
lie many instances of cancer sensitivity to cytotoxic chemo-
therapy.
Sensitizer BH3 mimetic small molecule inhibitors of antiapo-
ptotic proteins are currently in preclinical and clinical develop-
ment (Oltersdorf et al., 2005). Our results shed light on how
such agents might selectively case death in ‘‘primed’’ cells,
a state that may be preferentially occupied by cancer cells. Fur-
thermore, the binding code presented here suggests that the
binding pockets of the antiapoptotic proteins are structurally
and functionally distinct. Antiapoptotic proteins may therefore
be susceptible to individual targeting by drugs developed as
selective mimetics of sensitizer BH3 domains.
Experimental procedures
Reagents
ABT-737 and its negative control enantiomer, which has lower affinity for
BCL-2 family members, were obtained from Abbott Laboratories (Oltersdorf
et al., 2005).
GST pull-down
Ten micrograms GST-BCL-w (or BH3 binding-defective R96P point mutant)
were incubated with glutathione-agarose beads for 1 hr at 4ºC in binding
buffer (140 mM NaCl, 10 mM Tris [pH 7.4]). Beads were rinsed and incubated
with approximately 0.2 mg tBID for 1 hr at 4ºC. Beads were washed again and
incubated with peptides for 1 hr at 4ºC. tBID protein was eluted from beads
with 50 mM glutathione and loaded on a denaturing NuPAGE gel.
Cytochrome c release
Mitochondria were purified from liver and FL5.12 cells as previously de-
scribed (Letai et al., 2002). Mitochondria were purified from leukemia cells
and 2B4 cells as previously described for FL5.12 cells. Mitochondria were in-
cubated with treatments for 45 (mouse liver mitochondria) or 35 min (FL5.12,
2B4, and leukemic mitochondria). Release of cytochrome c was determined
by a comparison of cytochrome c in the pellet and supernatant following
treatment, quantitated by ELISA (R&D systems). When results of multiple ex-
periments were averaged, results from solvent-only (DMSO) treatments
values were subtracted from each, so that 0 release reflects that observed
in solvent-only treatments.
Other procedures are in the Supplemental Data.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
three supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/5/351/DC1/.
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